PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA - Jason Westin; Caron Jacobson; Julio C Chavez; Anna Sureda; Franck Morschhauser; Bertram Glass; Michael Dickinson; Andrew J. Davies; Ian W. Flinn; David Maloney; Martine Chamuleau; Michael Tees; et al. (HemaSphere, 2023)